{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:34:29Z","timestamp":1793831669154,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The global incidence of thyroid cancer (TC) has risen considerably during the last three decades, while prognosis is generally favorable. We assessed the long-term all-cause mortality in TC survivors compared to the general population, and its association with cardiovascular risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individuals diagnosed with TC during 2001\u20132014 (TC group) and age- and sex-matched individuals from the same Israeli healthcare system without thyroid disease or a cancer history (non-TC group) were compared. Cox regression hazard ratios (HRs) and 95% confidence intervals (95%CIs) for all-cause mortality were calculated by exposure status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During a 15-year follow-up (median 8\u2009years), 577 TC survivors out of 5677 (10.2%) TC patients and 1235 individuals out of 23,962 (5.2%) non-TC patients died. The TC survivors had an increased risk of all-cause mortality (HR\u2009=\u20091.89, 95%CI 1.71\u20132.10), after adjusting for cardiovascular risk factors already present at follow-up initiation. This increased risk was most pronounced in the 55- to 64-year-old age group (HR\u2009=\u20091.49, 95%CI 1.33\u20131.67). The TC survivors who died by study closure had more hypertension (14.6% vs. 10.3%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002), more dyslipidemia (11.4% vs. 7.2%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001), and more cardiovascular disease (33.6% vs. 22.3%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.05) compared to those who died in the non-TC group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This large cohort study showed higher all-cause mortality with a higher prevalence of hypertension, dyslipidemia, and cardiovascular disease among TC survivors compared to matched non-TC individuals. Primary and secondary prevention of cardiovascular risk factors in TC survivors is mandatory.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07401-3","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T11:15:30Z","timestamp":1600341330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term all-cause mortality and its association with cardiovascular risk factors in thyroid cancer survivors: an Israeli population-based study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4742-878X","authenticated-orcid":false,"given":"Elena","family":"Izkhakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lital","family":"Keinan-Boker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha","family":"Barchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacov","family":"Shacham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Yaish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narin N.","family":"Carmel Neiderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan M.","family":"Fliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naftali","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Meyerovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"7401_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","volume":"140","author":"L Davies","year":"2014","unstructured":"Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317\u201322.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"7401_CR2","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States,1974\u20132013. JAMA. 2017;317:1338\u201348.","journal-title":"JAMA"},{"key":"7401_CR3","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/ijc.29251","volume":"136","author":"C La Vecchia","year":"2015","unstructured":"La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187\u201395.","journal-title":"Int J Cancer"},{"key":"7401_CR4","doi-asserted-by":"crossref","unstructured":"Keinan-Boker L, Silverman BG. Trends of thyroid cancer in Israel: 1980\u20132012. Rambam Maimonides Med J. 2016;7(10):e0001.","DOI":"10.5041\/RMMJ.10228"},{"key":"7401_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.amjoto.2015.02.015","volume":"36","author":"B Oberman","year":"2015","unstructured":"Oberman B, Khaku A, Camacho F, Goldenberg D. Relationship between obesity, diabetes and the risk of thyroid cancer. Am J Otolaryngol. 2015;36:535\u201341.","journal-title":"Am J Otolaryngol"},{"key":"7401_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40618-014-0143-0","volume":"38","author":"A Gazdag","year":"2015","unstructured":"Gazdag A, Nagy EV, Erdei A, Bodor M, Berta E, Szab\u00f3 Z, et al. Aortic stiffness and left ventricular function in patients with differentiated thyroid cancer. J Endocrinol Investig. 2015;38:133\u201342.","journal-title":"J Endocrinol Investig"},{"key":"7401_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2265.2011.04138.x","volume":"75","author":"V Taillard","year":"2011","unstructured":"Taillard V, Sardinoux M, Oudot C, Fesler P, Rugale C, Raingeard I, et al. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinomapatients on TSH-suppressive therapy. Clin Endocrinol (Oxf). 2011;75:709\u201314.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"7401_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.2012.42.4457","volume":"31","author":"L Yang","year":"2013","unstructured":"Yang L, Shen W, Sakamoto N. Population based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol. 2013;31:468\u201374.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7401_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1530\/EC-19-0038","volume":"8","author":"E Izkhakov","year":"2019","unstructured":"Izkhakov E, Meyerovitch J, Barchana M, Shacham Y, Stern N, Keinan-Boker L. Long-term cardiovascular and cerebrovascular morbidity in Israeli thyroid cancer survivors. Endocr Connect. 2019;8(4):398\u201306.","journal-title":"Endocr Connect"},{"key":"7401_CR10","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1200\/JCO.2013.49.1043","volume":"31","author":"EN Klein Hesselink","year":"2013","unstructured":"Klein Hesselink EN, Klein Hesselink MS, de Bock GH, Gansevoort RT, Bakker SJ, Vredeveld EJ, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol. 2013;31:4046\u201353.","journal-title":"J Clin Oncol"},{"key":"7401_CR11","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1056\/NEJMp1409841","volume":"371","author":"HS Ahn","year":"2014","unstructured":"Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer \"epidemic\"\u2014screening and overdiagnosis. N Engl J Med. 2014;371:1765\u20137.","journal-title":"N Engl J Med"},{"key":"7401_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s00268-015-3322-z","volume":"40","author":"A Konturek","year":"2016","unstructured":"Konturek A, Barczy\u0144ski M, Stopa M, Nowak W. Trends in prevalence of thyroid cancer over three decades: a retrospective cohort study of 17,526 surgical patients. World J Surg. 2016;40:538\u201344.","journal-title":"World J Surg"},{"key":"7401_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/aje\/kwp354","volume":"171","author":"CL Meinhold","year":"2009","unstructured":"Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, Linet MS, et al. Nontraditional risk factors for thyroid cancer in the US radiologic technologists study. Am J Epidemiol. 2009;171:242\u201352.","journal-title":"Am J Epidemiol"},{"key":"7401_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1089\/thy.2015.0315","volume":"26","author":"IJ Nixon","year":"2016","unstructured":"Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC\/UICC staging system for well-differentiated thyroid Cancer. Thyroid. 2016;26:373\u201380.","journal-title":"Thyroid"},{"key":"7401_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1089\/thy.2015.0104","volume":"25","author":"I Ganly","year":"2015","unstructured":"Ganly I, Nixon IJ, Wang LY, Palmer FL, Migliacci JC, Aniss A, et al. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid. 2015;25:1106\u201314.","journal-title":"Thyroid"},{"key":"7401_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1210\/jc.2012-2458","volume":"98","author":"FA Verburg","year":"2013","unstructured":"Verburg FA, M\u00e4der U, Tanase K, Thies ED, Diessl S, Buck AK, et al. Life expectancy is reduced in differentiated thyroid cancer patients \u226545 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab. 2013;98:172\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"7401_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1089\/thy.2016.0481","volume":"27","author":"E Izkhakov","year":"2017","unstructured":"Izkhakov E, Barchana M, Liphshiz I, Silverman BG, Stern N, Keinan-Boker L. Trends of second primary malignancy in patients with thyroid cancer: a population-based cohort study in Israel. Thyroid. 2017;27(6):793\u201301.","journal-title":"Thyroid"},{"key":"7401_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1210\/jc.2007-1154","volume":"93","author":"AP Brown","year":"2008","unstructured":"Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Toward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504\u201315.","journal-title":"J Clin Endocrinol Metab"},{"key":"7401_CR19","doi-asserted-by":"crossref","unstructured":"Liou MJ, Tsang NM, Hsueh C, Chao TC, Lin JD. Therapeutic outcome of second primary malignancies in patients with well-differentiated thyroid cancer. Int J Endocrinol. 2016;2016:9570171.","DOI":"10.1155\/2016\/9570171"},{"key":"7401_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1365-2265.2006.02492.x","volume":"64","author":"JL Kuijpens","year":"2006","unstructured":"Kuijpens JL, Janssen-Heijnen ML, Lemmens VE, Haak HR, Heijckmann AC, Coebergh JW. Comorbidity in newly diagnosed thyroid cancer patients: a population-based study on prevalence and the impact on treatment and survival. Clin Endocrinol (Oxf.). 2006;64:450\u20135.","journal-title":"Clin Endocrinol (Oxf.)."},{"key":"7401_CR21","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/aje\/kwv290","volume":"183","author":"R Dankner","year":"2016","unstructured":"Dankner R, Boffetta P, Balicer RD, Keinan Boker L, Sadeh M, Berlin A, et al. Time-dependent risk of Cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183:1098\u201306.","journal-title":"Am J Epidemiol"},{"key":"7401_CR22","doi-asserted-by":"publisher","first-page":"e55179","DOI":"10.1371\/journal.pone.0055179","volume":"8","author":"ST Chen","year":"2013","unstructured":"Chen ST, Hsueh C, Chiou WK, Lin JD. Disease-specific mortality and secondary primary cancer in well-differentiated thyroid cancer with type 2 diabetes mellitus. PLoS One. 2013;8:e55179.","journal-title":"PLoS One"},{"key":"7401_CR23","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1002\/cncr.26070","volume":"117","author":"NG Iyer","year":"2011","unstructured":"Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117:4439\u201346.","journal-title":"Cancer"},{"key":"7401_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/cen.12581","volume":"83","author":"AR Khang","year":"2015","unstructured":"Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, et al. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131) I dose over 37 GBq. Clin Endocrinol (Oxf). 2015;83:117\u201323.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"7401_CR25","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/annonc\/mdp050","volume":"20","author":"R Sciuto","year":"2009","unstructured":"Sciuto R, Romano L, Rea S, Marandino F, Sperduti I, Maini C. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol. 2009;20:1728\u201335.","journal-title":"Ann Oncol"},{"key":"7401_CR26","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli J, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"7401_CR27","doi-asserted-by":"publisher","first-page":"E152","DOI":"10.25011\/cim.v35i3.16591","volume":"35","author":"A Abonowara","year":"2012","unstructured":"Abonowara A, Quraishi A, Sapp JL, Alqambar MH, Saric A, O'Connell CM, et al. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. Clin Invest Med. 2012;35:E152\u2013E56.","journal-title":"Clin Invest Med"},{"key":"7401_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/thy.2006.16.381","volume":"16","author":"M Shargorodsky","year":"2006","unstructured":"Shargorodsky M, Serov S, Gavish D, Leibovitz E, Harpaz D, Zimlichman R. Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid. 2006;16:381\u20136.","journal-title":"Thyroid"},{"key":"7401_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/jcem.85.1.6298","volume":"85","author":"G Mercuro","year":"2000","unstructured":"Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual.Dose.Tailoring. J Clin Endocrinol Metab. 2000;85:159\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"7401_CR30","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1210\/jc.2004-0536","volume":"89","author":"MK Horne 3rd","year":"2004","unstructured":"Horne MK 3rd, Singh KK, Rosenfeld KG, Wesley R, Skarulis MC, Merryman PK, et al. Is thyroid hormone suppression therapy prothrombotic? J Clin Endocrinol Metab. 2004;89:4469\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"7401_CR31","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1089\/thy.2010.0319","volume":"21","author":"RM Abdulrahman","year":"2011","unstructured":"Abdulrahman RM, Delgado V, Hoftijzer HC, Ng AC, Ewe SH, Marsan NA, et al. Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma. Thyroid. 2011;21:471\u20136.","journal-title":"Thyroid"},{"key":"7401_CR32","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1001\/archinternmed.2012.402","volume":"172","author":"TH Collet","year":"2012","unstructured":"Collet TH, Gussekloo Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172:799\u2013809.","journal-title":"Arch Intern Med"},{"key":"7401_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1871530311313010003","volume":"13","author":"B Gencer","year":"2013","unstructured":"Gencer B, Collet TH, Virgini V, Auer R, Rodondi N. Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies. Endocr Metab Immune Disord Drug Targets. 2013;13:4\u201312.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"7401_CR34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12020-016-0877-x","volume":"53","author":"G Kaminski","year":"2016","unstructured":"Kaminski G, Dziuk M, Szczepanek-Parulska E, Zybek-Kocik A, Ruchala M. Electrocardiographic and scintigraphic evaluation of patients with subclinical hyperthyroidism during workout. Endocrine. 2016;53:512\u20139.","journal-title":"Endocrine"},{"key":"7401_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1210\/jc.2010-2693","volume":"96","author":"T Vadiveloo","year":"2011","unstructured":"Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The thyroid epidemiology, audit, and research study (TEARS): morbidity in patients with endogenous suclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96:1344\u201351.","journal-title":"J Clin Endocrinol Metab"},{"key":"7401_CR36","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1210\/jc.2013-4184","volume":"99","author":"C Selmer","year":"2014","unstructured":"Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab. 2014;99:2372\u201382.","journal-title":"J Clin Endocrinol Metab"},{"key":"7401_CR37","doi-asserted-by":"crossref","unstructured":"Hong KS, Son JW, Ryu OH, Choi MG, Hong JY, Lee SJ. Cardiac effects of thyrotropin oversuppression with levothyroxine in young women with differentiated thyroid Cancer. Int J Endocrinol. 2016;2016:9846790.","DOI":"10.1155\/2016\/9846790"},{"key":"7401_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3109\/0284186X.2015.1102965","volume":"55","author":"C Hedman","year":"2016","unstructured":"Hedman C, Dj\u00e4rv T, Strang P, Lundgren CI. Determinants of long-term quality of of life in patients with differentiated thyroid carcinoma - a population-based.cohort.study in Sweden. Acta Oncol. 2016;55:365\u20139.","journal-title":"Acta Oncol"},{"key":"7401_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/psy.0b013e318068fcd4","volume":"69","author":"PK Myint","year":"2007","unstructured":"Myint PK, Luben RN, Surtees PG, Wainwright NW, Welch AA, Bingham SA, et al. Self-reported mental health-related quality of life and mortality in men and women in the European prospective investigation into Cancer (EPIC-Norfolk): a prospective population study. Psychosom Med. 2007;69:410\u20134.","journal-title":"Psychosom Med"},{"key":"7401_CR40","doi-asserted-by":"publisher","first-page":"e101527","DOI":"10.1371\/journal.pone.0101527","volume":"9","author":"G Xie","year":"2014","unstructured":"Xie G, Laskowitz DT, Turner EL, Egger JR, Shi P, Ren F, et al. Baseline health-related quality of life and 10-year all-cause mortality among 1739 Chinese adults. PLoS One. 2014;9:e101527.","journal-title":"PLoS One"},{"key":"7401_CR41","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1158\/1078-0432.CCR-15-1746","volume":"22","author":"M \u015awierniak","year":"2016","unstructured":"\u015awierniak M, W\u00f3jcicka A, Czetwerty\u0144ska M, D\u0142ugosi\u0144ska J, Stachlewska E, Gierlikowski W, et al. Association between GWAS-derived rs966423 genetic variant and overall mortality in patients with differentiated thyroid cancer. Clin Cancer Res. 2016;22:1111\u20139.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07401-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07401-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07401-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T19:19:38Z","timestamp":1631819978000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07401-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7401"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07401-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-39122\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-39122\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-39122\/v3","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"assertion":[{"value":"27 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Helsinki Medical Ethics Committee of the Clalit Health Services provided approval to conduct this study (approval # 0040\u201315-COM) and waived signed informed consent since the study was based on existing databases.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"892"}}